Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

An outpatient nephrology consultation is requested for a male patient who received a deceased-donor renal allograft four months prior. The patient reports a five-day history of persistent headaches, insomnia, and bilateral hand tremors that interfere with his ability to eat. He has also noticed a decline in his daily urine output. His maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and low-dose prednisone. Thirteen days ago, he was evaluated by an infectious disease specialist for invasive pulmonary aspergillosis, for which oral voriconazole therapy was initiated.

Vital signs today demonstrate a blood pressure of 168/98 mmHg, heart rate of 88/min, and temperature of 37.2°C (99.0°F). Physical examination reveals a fine, bilateral resting tremor in the upper extremities but is otherwise unremarkable.

Laboratory analysis shows:
TestResultReference Range
Blood urea nitrogen34 mg/dL8-20 mg/dL
Serum creatinine2.2 mg/dL0.7-1.3 mg/dL
Baseline creatinine (1 month ago)1.2 mg/dL0.7-1.3 mg/dL

Urinalysis is unremarkable with no proteinuria or cellular casts.

Which of the following is the most appropriate next step in the management of this patient?

  1. Check a serum tacrolimus trough concentration and decrease the dosageCevap
  2. B
    Schedule an urgent ultrasound-guided percutaneous allograft biopsy
  3. C
    Substitute mycophenolate mofetil with azathioprine
  4. D
    Administer high-dose intravenous methylprednisolone pulse therapy
  5. E
    Order Doppler ultrasonography of the transplanted renal vasculature

Cevap

Check a serum tacrolimus trough concentration and decrease the dosage
The correct approach addresses calcineurin inhibitor (CNI) toxicity. Tacrolimus is a CNI metabolized by the hepatic and intestinal cytochrome P450 3A4 (CYP3A4) system. Voriconazole is a potent inhibitor of CYP3A4. Co-administration significantly decreases tacrolimus clearance, leading to supratherapeutic levels. CNI toxicity typically presents with acute kidney injury (due to afferent arteriolar vasoconstriction), new-onset or worsening hypertension, and neurotoxicity (ranging from fine tremors and headaches to seizures). The most appropriate next step is to check a serum tacrolimus trough concentration and reduce the dosage to prevent further toxicity.

Adım Adım Çözüm

1
Identify the patient's clinical syndrome.
The patient presents with acute kidney injury, new-onset hypertension, and neurotoxicity (tremors, headaches, insomnia).
Characterizing the constellation of symptoms narrows the differential diagnosis in a post-transplant patient.
2
Analyze the patient's medication history for potential adverse effects or interactions.
The patient recently started voriconazole while on a maintenance regimen of tacrolimus.
Drug-drug interactions are a primary cause of morbidity in transplant patients on complex pharmacological regimens.
3
Determine the mechanism of the interaction and its clinical consequences.
Voriconazole strongly inhibits CYP3A4, the enzyme responsible for metabolizing tacrolimus, leading to supratherapeutic tacrolimus levels and subsequent calcineurin inhibitor toxicity.
Understanding the pharmacokinetic mechanism allows for the correct intervention.
4
Select the most appropriate management step.
Checking a tacrolimus trough level and preemptively reducing the dose directly addresses the root cause of the patient's symptoms.
Drug level monitoring and dose adjustment is the standard of care for suspected calcineurin inhibitor toxicity.

Anahtar Kavram

Voriconazole strongly inhibits CYP3A4, reducing the metabolism of calcineurin inhibitors (like tacrolimus and cyclosporine). This leads to supratherapeutic levels and toxicity, manifesting as nephrotoxicity, neurotoxicity, and hypertension, requiring urgent therapeutic drug monitoring and dose reduction.

Alternatif Yöntem

In clinical practice, when starting a potent CYP3A4 inhibitor in a patient on tacrolimus, the tacrolimus dose is often empirically reduced by 30-50% simultaneously with the initiation of the new drug, followed by close therapeutic drug monitoring.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru